Biotech News & Trading Forum: Community User: Weedmaster

😁😁😁

Heute sind die I Aktien dran I wie Intellipharmaceutics und I wie Inflarx 😁

Nantkwest nicht schlecht

Zosano Pharma will noch im Dezember einen NDA für Qtrypta stellen https://www.globenewswire.com/news-release/2019/11/13/1946752/0/en/Zosano-Pharma-Announces-Completion-of-Pre-NDA-Meetings-with-FDA-for-Qtrypta.html

ja Tocagen sieht heute übel aus. Gestern hui heute pfui. 🙄

Bei inflarx siehts ein bissl nach bullischer fahne aus, aber kenn mich da noch zu wenig aus 😅

Toca wieder alles weg und mehr 🤔

Bin ich auch Schorsch. 😅

Moma bei IPCI müsstest du jetzt im Plus sein

Zartes grün bei Inflarx.

https://www.sickeconomics.com/2019/01/25/3-signs-biotech-acquired/

IND approval müsste morgen oder anfang nächste Woche kommen könnte wieder für einen kräftigen Kursschub sorgen.....Biophytis (ALBPS) ..Kurs: 0,20 --unfassbar niedrige Marktkap von nur €3 M --Cashbestand €5,2 M --Phase 2b läuft für die Sarkopenie Studie eine *** für das es bisher KEIN zugelassenes Medikament gibt und Start Phase 1/2 in DMD in kürze =MULTIBAGGER Potential--für mehr Infos link unten folgen .......https://www.wallstreet-online.de/diskussion/1316420-1-10/albps-pa-mkap-2-9-m-attraktive-pipeline-u-spottbillig

Bin mal klein bei Tonix mit dabei

Fleißig fleißig 😅

NEW YORK, Dec. 11, 2019 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced that the European Patent Office ("EPO") issued European Patent No. 2968992 to the Company on December 11, 2019. This patent, “Eutectic Formulations of Cyclobenzaprine Hydrochloride and Mannitol,” includes 14 claims directed to compositions comprising eutectics of cyclobenzaprine hydrochloride and mannitol and methods of making those compositions. This patent is expected to provide Tonix with market exclusivity until 2034. Seth Lederman, M.D., President and Chief Executive Officer of Tonix commented, “The issuance of this European patent is an important step forward in our efforts to broaden our intellectual property estate on a global basis for TNX-102 SL*.” Tonix’s proprietary eutectic formulation of cyclobenzaprine, or TNX-102 SL, is designed for chronic sublingual (under-the-tongue) administration daily at bedtime, which the Company believes facilitates transmucosal absorption of cyclobenzaprine and bypasses first pass liver metabolism. Marketed cyclobenzaprine drug products are limited to short-term use (two to three weeks) and formulated for oral ingestion, which results in significant liver metabolism. Sublingual TNX-102 SL has a different pharmacokinetic profile than marketed oral cyclobenzaprine drug products. TNX-102 SL is being developed as a treatment for four indications: posttraumatic stress disorder (PTSD), fibromyalgia, agitation in Alzheimer’s disease and alcohol use disorder. Marketed oral cyclobenzaprine products are indicated for the relief of muscle spasm.

$TNXP closed strong in after-hours +25% trading nearly the entire float. After CEI, i think the money will flow into this name. Squeeze over 1.30 targeting the 2.25 zone. Plus, there is a gap to fill over 1.87. As i said on $CEI when it comes to low float names, everything is possible, they can double or triple in a single day and volume precedes price. Usually, before a stock price moves, the volume comes into play. The after-hours trading, was the signal.